Application 207818
- Type
- ANDA
- Sponsor
- NATCO PHARMA LTD
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | IMATINIB MESYLATE | IMATINIB MESYLATE | TABLET;ORAL | EQ 100MG BASE | No | No |
| 002 | IMATINIB MESYLATE | IMATINIB MESYLATE | TABLET;ORAL | EQ 400MG BASE | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A207818-001 | IMATINIB MESYLATE | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | AB | 2019-03-01 | |
| A207818-002 | IMATINIB MESYLATE | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | AB | 2019-03-01 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A207818-001 | AB |
| A207818-002 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A207818-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | AB | 2019-03-01 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A207818-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | AB | 2019-03-01 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A207818-001 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A207818-002 | AB | 1 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Imatinib Mesylate | IMATINIB MESYLATE | Apotex Corp | 0291eca5-7a1d-4a79-30be-252224d96509 | 2026-07-28 | Warnings, Adverse reactions | Imatinib Mesylate IMATINIB MESYLATE |
| Gleevec | IMATINIB MESYLATE | Novartis Pharmaceuticals Corporation | 211ef2da-2868-4a77-8055-1cb2cd78e24b | 2026-07-13 | Warnings, Adverse reactions | IMATINIB MESYLATE |
| IMATINIB MESYLATE | IMATINIB MESYLATE | Civica Script LLC | 9fc5ec7b-98c4-4b1a-890c-be1343177dbd | 2026-07-03 | Warnings, Adverse reactions | IMATINIB MESYLATE IMATINIB MESYLATE |
| Imatinib Mesylate | IMATINIB | Golden State Medical Supply, Inc. | 9131b2ce-752d-3a30-e053-2a95a90adaab | 2026-06-16 | Warnings, Adverse reactions | Imatinib Mesylate |
| imatinib mesylate | IMATINIB MESYLATE | Sun Pharmaceutical Industries, Inc. | 07764bf9-21b4-4e32-9d7e-e348f8e4291f | 2026-06-01 | Warnings, Adverse reactions | imatinib mesylate IMATINIB MESYLATE |
| Imatinib Mesylate | IMATINIB MESYLATE | BluePoint Laboratories | c0611fc0-b217-4988-acd4-b8c629ce489b | 2026-05-21 | Warnings, Adverse reactions | Imatinib Mesylate IMATINIB MESYLATE |
| Imatinib Mesylate | IMATINIB | Mylan Pharmaceuticals Inc. | a1787fad-3612-43e1-98fa-ce62361e0b3c | 2026-05-05 | Warnings, Adverse reactions | Imatinib Mesylate |
| Imatinib Mesylate | IMATINIB MESYLATE | Teva Pharmaceuticals USA, Inc. | a9cfc301-3c7f-4910-8813-41dcb0b4ca69 | 2026-04-29 | Warnings, Adverse reactions | Imatinib Mesylate IMATINIB MESYLATE |
| Imatinib Mesylate | IMATINIB | Safecor Health, LLC | f4acacbd-13f8-4a46-b615-b639a17f331f | 2026-04-17 | Warnings, Adverse reactions | Imatinib Mesylate |
| Imatinib Mesylate | IMATINIB MESYLATE | Aurobindo Pharma Limited | a4e409f7-20b4-4c80-8a6a-f95995ffad78 | 2026-03-13 | Warnings, Adverse reactions | Imatinib Mesylate IMATINIB MESYLATE |
| Imatinib Mesylate | IMATINIB MESYLATE | Major Pharmaceuticals | 7c037022-7fc8-4b6e-9db3-427206c572b4 | 2026-02-13 | Warnings, Adverse reactions | Imatinib Mesylate IMATINIB MESYLATE |
| imatinib mesylate | IMATINIB MESYLATE | Upsher-Smith Laboratories, LLC | 5d07ac08-962e-41a8-8a3c-50febc8c5f34 | 2026-01-09 | Warnings, Adverse reactions | imatinib mesylate IMATINIB MESYLATE |
| Imatinib Mesylate | IMATINIB MESYLATE | Chartwell RX, LLC | 65b4d8a6-349d-4fb1-9818-dad6b4ad4fa1 | 2025-12-10 | Warnings, Adverse reactions | Imatinib Mesylate IMATINIB MESYLATE |
| IMATINIB MESYLATE | IMATINIB MESYLATE | Camber Pharmaceuticals, Inc. | e97f0238-b9da-46af-83a3-0826e39893e8 | 2025-11-25 | Warnings, Adverse reactions | IMATINIB MESYLATE IMATINIB MESYLATE |
| Imatinib Mesylate | IMATINIB | Mylan Institutional Inc | 1debf3a0-7587-47d7-8ea6-e739698d7297 | 2025-09-15 | Warnings, Adverse reactions | Imatinib Mesylate |
| Imatinib Mesylate | IMATINIB MESYLATE | American Health Packaging | 6e7ed4ef-24e3-4545-9a99-2e34c946e8e7 | 2025-02-19 | Warnings, Adverse reactions | Imatinib Mesylate IMATINIB MESYLATE |
| imatinib mesylate | IMATINIB MESYLATE | Qilu Pharmaceutical Co., Ltd. | 82eb01e0-8685-4f06-8a72-7663e8ded38f | 2024-12-04 | Warnings, Adverse reactions | imatinib mesylate IMATINIB MESYLATE |
| imatinib mesylate | IMATINIB MESYLATE | BluePoint Laboratories | be5b9047-155b-59ca-e053-2995a90ad3dc | 2023-09-21 | Warnings, Adverse reactions | imatinib mesylate IMATINIB MESYLATE |
| imatinib mesylate | IMATINIB MESYLATE | Archis Pharma LLC | 9de8d8b9-cf88-4960-82b7-89e5ceb7720e | 2023-09-21 | Warnings, Adverse reactions | imatinib mesylate IMATINIB MESYLATE |
| Imatinib Mesylate | IMATINIB MESYLATE | QUALLENT PHARMACEUTICALS HEALTH LLC | a819a954-41c9-4d49-a74e-c8c4b338b22a | 2023-09-16 | Warnings, Adverse reactions | Imatinib Mesylate IMATINIB MESYLATE |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 68180-390 | IMATINIB MESYLATE | IMATINIB | Lupin Pharmaceuticals, Inc. | ANDA | Current |
| 68180-390 | IMATINIB MESYLATE | IMATINIB | Lupin Pharmaceuticals, Inc. | ANDA | Current |
| 68180-391 | IMATINIB MESYLATE | IMATINIB | Lupin Pharmaceuticals, Inc. | ANDA | Current |
| 68180-391 | IMATINIB MESYLATE | IMATINIB | Lupin Pharmaceuticals, Inc. | ANDA | Current |